Oxygen Of The Saccharide Radical Bonded To A Nonsaccharide Hetero Ring By Acyclic Carbon Bonding Patents (Class 514/32)
-
Publication number: 20120214756Abstract: The present invention relates to an intermolecular association complex of an amphiphilic carrier and an active principle G, having the following general formula (I), as well as to the compositions containing same, to the uses thereof, particularly as a drug, and to the method for preparing same.Type: ApplicationFiled: October 4, 2010Publication date: August 23, 2012Applicants: UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Cécile Bize, Muriel Blanzat, Emile Perez, Isabelle Rico-Lattes
-
Publication number: 20120128662Abstract: The present invention relates to substituted imidazoquinoxaline compounds of general formula (I) as inhibitors of Mps-1 Kinase or TTK, and being active against inflammation and cancer.Type: ApplicationFiled: April 24, 2010Publication date: May 24, 2012Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Marcus Koppitz, Benjamin Bader, Ulf Bömer, Bertolt Kreft, Philip Lienau, Tobias Marquardt, Stefan Prechtl, Gerhard Siemeister, Christof Wegscheid-Gerlach
-
Patent number: 8178658Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.Type: GrantFiled: February 11, 2009Date of Patent: May 15, 2012Assignee: Dow AgroSciences, LLCInventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
-
Publication number: 20120101054Abstract: Novel sodium channel blocking compounds tetrodotoxm galactopyranosides of formula I were isolated and purified by HPLC and identified further through IR, NMR, GC, and MS. The compounds have a galactopyranosyl moiety attached to C11 of tetrodotoxin and retain the analgesic activity of the latter. Pharmaceutical compositions and medical uses thereof are further disclosed.Type: ApplicationFiled: March 26, 2010Publication date: April 26, 2012Applicant: Wex Medical LimitedInventor: Weiyang Lin
-
Publication number: 20120076851Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: ApplicationFiled: May 24, 2011Publication date: March 29, 2012Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Publication number: 20120070410Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.Type: ApplicationFiled: November 5, 2009Publication date: March 22, 2012Inventors: Julius L. Apuy, Darren E. Insko, Joyce J. James
-
Publication number: 20120045412Abstract: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.Type: ApplicationFiled: October 28, 2011Publication date: February 23, 2012Applicant: Gilead Sciences, Inc.Inventors: Lawrence S. Melvin, JR., Michael Graupe, Chandrasekar Venkataramani, Juan A. Guerrero
-
Publication number: 20120035115Abstract: The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.Type: ApplicationFiled: September 23, 2009Publication date: February 9, 2012Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Takeshi Yamada, David Butler, K. Narayanannair Jayaprakash, Muthusamy Jayraman, Shigeo Matsuda, Rajendra K. Pandey, Chang Geng Peng
-
Patent number: 8076302Abstract: A novel pyrimidine nucleoside derivative represented by the following formula (1) and a salt thereof, as well as a pharmaceutical composition comprising the same as an active ingredient have excellent antiviral properties and are useful as antiviral therapeutic agents: [wherein R represents a nitrogen-containing heterocyclic ring which may have any one of a C1-C3 alkyl group or a C1-C3 alkoxy group as a substituent, or a C1-C6 alkyl group which has one primary amino group as a substituent].Type: GrantFiled: February 15, 2007Date of Patent: December 13, 2011Assignee: aRigen Pharmaceuticals, Inc.Inventors: Haruhiko Machida, Masaichi Yamamoto
-
Patent number: 8058247Abstract: An antibacterial agent having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is provided. Specifically, the antibacterial agent of the present invention having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is a caprazamycin derivative represented, for example, by the following general formula (II): wherein Me is a methyl group; and R1 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms, a straight chain alkoxy group having 1 to 9 carbon atoms or a cycloalkyl group having 5 to 12 carbon atoms.Type: GrantFiled: February 11, 2009Date of Patent: November 15, 2011Assignees: Microbial Chemistry Research Foundation, Meiji Seika Kaisha, Ltd.Inventors: Yoshiaki Takahashi, Masayuki Igarashi
-
Publication number: 20110224158Abstract: The invention provides esterified ?-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein R1 is a hydrocarbon group having a carbon number of 1 to 30, R2 is a hydrocarbon group having a carbon number of 1 to 20, R3 is a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, R4 and R5 are the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or R4 and R5 in combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.Type: ApplicationFiled: September 11, 2009Publication date: September 15, 2011Applicant: RIKENInventors: Masao Shiozaki, Takuya Tashiro, Kenji Mori, Ryusuke Nakagawa, Hiroshi Watarai, Masaru Taniguchi
-
Publication number: 20110177999Abstract: The present invention relates to therapeutic combinations and kits useful in treating CFTR-related diseases, such as cystic fibrosis.Type: ApplicationFiled: August 7, 2008Publication date: July 21, 2011Inventors: Ashvani Singh, Jennings Franklin Worley, Gregor Zlokamik
-
Publication number: 20110098240Abstract: The invention relates to a pharmaceutical composition according to claim 1 comprising a SGLT2 inhibitor in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.Type: ApplicationFiled: August 15, 2008Publication date: April 28, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Klaus Dugi, Michael Mark, Frank Himmelsbach
-
Publication number: 20110086810Abstract: The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.Type: ApplicationFiled: October 8, 2010Publication date: April 14, 2011Applicant: INCYTE CORPORATIONInventors: James D. RODGERS, Adam SHILLING, Argyrios G. ARVANITIS, Stacey SHEPARD, Laurine G. GALYA, Mei LI, Frank M. NEDZA
-
Publication number: 20110071097Abstract: The present invention provides novel cephalotaxus esters, syntheses thereof, and intermediates thereto. The invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of using said compounds or compositions in the treatment of proliferative diseases (e.g., benign neoplasm, cancer, inflammatory disease, autoimmune disease, diabetic retinopathy) and infectious disease. The invention further provides methods of using said compounds or compositions in the treatment of multidrug resistant cancer.Type: ApplicationFiled: March 3, 2009Publication date: March 24, 2011Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: David Gin, Jeremy Wilmot, Hakim Djaballah
-
Publication number: 20110033565Abstract: Disclosed are novel protective compositions for dermal papilla cells. In an embodiment the protective compositions of the present invention comprise 0.25% w/w or above of compositions comprising at least 10% w/w and above of 1-O-galloyl-?-D-glucose (?-glucogallin). In an embodiment, the said protective composition additionally comprises 50% to greater than 50% gallates including mucic acid 1,4-lactone 5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-Methyl ester 2-O-gallate, mucic acid 1-Methyl ester 2-O-gallate and ellagic acid. In another embodiment the invention also encompasses synergistic protective compositions comprising the said protective compositions and 0.5% concentrate of liquid endosperm of Cocos nucifera, for dermal papilla directed towards helping the dermal papilla cells to form sufficient numbers and to retain a healthy morphology conducive for hair growth.Type: ApplicationFiled: August 7, 2009Publication date: February 10, 2011Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Beena Bhat, Geetha Kanhangad-Gangadharan, Susmitha Anand-Tathapudi, Pritee Paliwal
-
Publication number: 20110014204Abstract: The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed to prevent tumor development in subjects at risk for developing colorectal cancer (CRC). The present invention also relates to methods of identifying increased risk in developing CRC in a subject, including methods of assessing the efficacy of a chemotherapeutic regimen. Further, the present invention relates to methods for identifying anti-neoplastic agents.Type: ApplicationFiled: December 7, 2007Publication date: January 20, 2011Inventors: Andrew P. Feinberg, Andre Levchenko, Dan L. Longo, Minoru S.H. Ko
-
Publication number: 20100322880Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R3, R4 have the meaning cited in the claims, to methods for the production thereof, to agents containing said compounds and to their use for the functionalisation of matrices, in particular their use as skin and/or hair-binding UV filters.Type: ApplicationFiled: January 14, 2009Publication date: December 23, 2010Inventors: Thomas Rudolph, Philipp Buehle
-
Publication number: 20100298248Abstract: The present invention provides a compound of the formula (I) or (II, wherein R1 is H, alkyl, alkenyl or aryl, R2 is H, alkyl or aryl, R3 is H, a alkyl, alkenyl or aryl, R4 and R4-R8 are independently R10, C(O)R10 or SO2R10, wherein R10 is H, alkyl, alkenyl or aryl, and R9 is R9a, C(O)R9a or SO2R9a, wherein R9a is H, alkyl, alkenyl or aryl. R9a can be unsubstituted or substituted with one or more oxo(?O), OR9b, OC(O)R9b, OSO2R9b, NHR9b, NHC(O)R9b and NHSO2R9b groups. R9b is H, alkyl, alkenyl, or aryl. R9b can be unsubstituted or substituted with one or more groups such as oxo(?O), OR9c, CO2R9c, CO2R9c and OC(O)R9c. R9c is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent.Type: ApplicationFiled: August 6, 2010Publication date: November 25, 2010Applicant: The U.S.A., as represented by the secretary, Department of Health and Human ServicesInventors: Michael R. Boyd, Kirk R. Gustafson, Charles L. Cantrell
-
Patent number: 7829542Abstract: Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ cyclic AGPs for selectively stimulating immune responses in animals and plants.Type: GrantFiled: May 30, 2008Date of Patent: November 9, 2010Assignee: Corixa CorporationInventors: Jory R. Baldridge, David A. Johnson, Christopher W. Cluff
-
Publication number: 20100221211Abstract: The invention relates to a compound of general formula (I-0): wherein R1 means a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, or a C3-C6 cycloalkyl group; R2, R3, R4 and R5 mean a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a C1-C6 alkoxy group, or a halo-C1-C6 alkoxy group; R6 means a hydrogen atom, or a C1-C6 alkyl group; R7a means a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a C1-C6 alkoxy group, a hydroxy-C1-C6 alkyl group, -Q2-N(R1c)R1d or a nitrogen-containing heterocyclic group; R8a means a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a C1-C6 alkoxy group or a hydroxy-C1-C6 alkyl group; or R7a and R8a form, as taken together, a C2-C6 alkylene group, or R7a and R8a and the ring atoms to which they bond may form a spiro ring or a bicyclo ring; and X and Y mean a methine group or a nitrogen atom.Type: ApplicationFiled: October 20, 2008Publication date: September 2, 2010Inventors: Hidetomo Furuyama, Mikako Kawamura, Toshihiro Sakamoto, Fuyuki Yamamoto, Takashi Yoshizumi
-
Patent number: 7781410Abstract: The present invention features composition comprising a chalcone and the use thereof for treating acne and reducing the appearance of oil or pores on the skin, hair and scalp.Type: GrantFiled: August 4, 2006Date of Patent: August 24, 2010Assignee: Johnson & Johnson Consumer Companies, Inc.Inventors: Claude Saliou, Sekhar Boddupalli, Khalid Mahmood, Michael Anthonavage, Kelly Huang
-
Publication number: 20100173860Abstract: Compositions of purified and biologically active ellagitannins are provided by separation from pomegranate husk using a method of extraction and purification using a solid polymeric adsorbent and the uses of the said compoundsType: ApplicationFiled: December 24, 2009Publication date: July 8, 2010Inventors: Navindra P. Seeram, David Heber
-
Patent number: 7704988Abstract: This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.Type: GrantFiled: October 4, 2006Date of Patent: April 27, 2010Assignee: Merck & Co., Inc.Inventors: Robert J. DeVita, Gregori J. Morriello, Peter Lin
-
Publication number: 20100099636Abstract: A hydrous gel substantially comprising at least two polymers selected from the group consisting of polyacrylic acid, sodium polyacrylate and partially neutralized polyacrylate, and water, the polymers being crosslinked by containing an aluminum compound, wherein the pH when the hydrous gel is 100-fold diluted with purified water is from 6.5 to 8.5. A hydrous gel which can stably hold an ascorbic acid or a derivative thereof, has high gel strength, exhibits good adhesion to an adherend and causes no liquid syneresis can be provided.Type: ApplicationFiled: December 18, 2009Publication date: April 22, 2010Applicant: SHOWA DENKO K.K.Inventor: Tetsuya ISHII
-
Publication number: 20100093651Abstract: This disclosure provides improved derivatives of artemisinin; pharamaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventing, controlling or treating infectious diseases including but not limited to parasitic infectious diseases such as T. gondii infection, trypanosome parasite infection, plasmodia parasite infection, and cryptosporidium parasite infection; methods for preventing, controlling or treating toxoplasma infection; and methods for treating psychiatric disorders associated with toxoplasma infection including but not limited to schizophrenia using the disclosed compounds and compositions alone or in combination with one or more antipsychotic drugs.Type: ApplicationFiled: October 19, 2007Publication date: April 15, 2010Inventors: Lorraine V. Brando, Gary H. Posner, John G. D'Angelo, Robert H. Yolken, Christopher P. Hencken, Lauren Woodard
-
Publication number: 20100093652Abstract: A topical formulation that inhibits the growth of microorganisms comprises an effective amount of an insecticide dissolved in an oil phase comprising a water-miscible or water-soluble surface active agent, a suspending agent, and a non-ionic surfactant, and an aqueous phase comprising one or more preservatives, where the aqueous phase is buffered to a specific pH. The overall antimicrobial efficacy in an emulsion formulation can be enhanced by buffering the aqueous phase of the emulsion to a pH at which the preservative system inhibits growth for a wider variety of microorganism types in the formulation relative to the equivalent formulation in which the aqueous phase is not buffered.Type: ApplicationFiled: October 29, 2009Publication date: April 15, 2010Applicant: Topaz Pharmaceuticals Inc.Inventors: Nicholas Spring, Edward J. Delaney
-
Publication number: 20100034792Abstract: This invention provides combinations of at least one biological control agent and at least one nematicide to enhance plant protection against pests and pathogens.Type: ApplicationFiled: June 18, 2007Publication date: February 11, 2010Applicant: The Regents of the University of CaliforniaInventor: Jorn Ole Becker
-
Publication number: 20100034762Abstract: Improved methods to prepare aqueous extracts of gallic acid esters including 1-O-galloyl-?-D-glucose (?-glucogallin) and other mucic acid gallates from the fruits of Emblica officinalis, wherein enrichment of gallic acid esters is achieved by Supercritical Fluid Extraction (SCFE) procedure, are disclosed. The use of such standardized extracts of gallic acid esters (greater than 40% w/w of gallic acid esters) in the manufacture of medicaments with diverse health benefits, is also disclosed.Type: ApplicationFiled: September 10, 2008Publication date: February 11, 2010Inventors: Muhammed Majeed, Atul Namdevrao Jadhav, Jyotish Shanker Srivastava, Subbalakshmi Prakash, Kalyanam Nagabhushanam, Beena Bhat
-
Publication number: 20100009925Abstract: The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.Type: ApplicationFiled: August 31, 2009Publication date: January 14, 2010Inventors: Youe-Kong Shue, Chan-Kou Hwang, Yu-Hung Chiu, Alex Romero, Farah Babakhani, Pamela Sears, Franklin Okumu
-
Publication number: 20090306003Abstract: An improved pesticide delivery system is disclosed. The system is based on a microblend comprising (a) an amphophilic compound containing at least one hydrophilic group and at least one hydrophobic group and (b) a second compound. Compositions based on the microblend and methods of using the compositions to control pests are also disclosed.Type: ApplicationFiled: January 10, 2007Publication date: December 10, 2009Applicant: Innovation Technologies, LLCInventors: Alexander V. Kabanov, Tatiana K. Bronitch, Michael Karas, Bruce L. Frank
-
Publication number: 20090291904Abstract: The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers.Type: ApplicationFiled: December 7, 2006Publication date: November 26, 2009Inventors: Yoel Kashman, Eliezer Flescher, Max Herzberg
-
Patent number: 7622449Abstract: This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.Type: GrantFiled: June 15, 2005Date of Patent: November 24, 2009Assignee: Merck & Co., Inc.Inventors: Mark T. Goulet, Feroze Ujjainwalla, Anthony Ogawa, Derek Von Langen
-
Publication number: 20090239814Abstract: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z?)(Z?)O-nucleoside, —P(Z?)(Z?)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z?)(Z?)O-Linker-OP(Z??)(Z??)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z?)(Z?)-formula (I), —P(Z?)(Z?)— or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g.Type: ApplicationFiled: December 4, 2008Publication date: September 24, 2009Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Narayanannair, Martin Maier
-
Publication number: 20090232756Abstract: A composition in the form of an oil-in-water emulsion containing: an ester of fatty acid and of polyethylene glycol; an additional surfactant chosen from esters of C16-C22 fatty acid and of sorbitan and esters of C16-C22 fatty acid and of glycerol; a polycondensate of ethylene oxide and of propylene oxide consisting of polyethylene glycol and polypropylene glycol blocks; and an ascorbic acid compound or a salicylic acid compound. The composition has good stability, in particular after hours at 55° C. Application in caring for and making up keratinous substances.Type: ApplicationFiled: March 9, 2009Publication date: September 17, 2009Applicant: L'OREALInventor: Aldo MONELLO
-
Publication number: 20090227528Abstract: The invention relates to the use of an oligosaccharide conjugated to a direct thrombin inhibitor for the manufacture of a medicament for the pulmonary delivery of said compound for the prevention or treatment of thrombosis or related disorders.Type: ApplicationFiled: October 3, 2005Publication date: September 10, 2009Applicant: N.V. OrganonInventor: Gerardus Martinus Theodorus Vogel
-
Publication number: 20090215707Abstract: The present invention relates to a compound represented by the following formula (1?) wherein R is an aldopyranose residue, R2 is a C2-18 hydrocarbon group optionally having substituent(s), R3 is an acyl group, X is an oxygen atom, a sulfur atom or —NH—, and p is an integer of 0-4, or a salt thereof. The compound of the present invention has a specific immunoregulatory ability, and is useful for the prophylaxis or treatment of autoimmune diseases and the like.Type: ApplicationFiled: March 3, 2006Publication date: August 27, 2009Applicant: RIKENInventors: Ken-ichi Fuhshuku, Kenji Mori, Takuya Tashiro, Masaru Taniguchi, Ken-ichiro Seino
-
Publication number: 20090048186Abstract: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.Type: ApplicationFiled: April 19, 2005Publication date: February 19, 2009Inventors: Vishwajanani Jitendra Sattigeri, Sudershan K. Arora, Mohammad Salman, Venkata P. Palle, Ashis Mukherjee, Abhijit Ray, Raj Kumar Shirumalla
-
Publication number: 20090042816Abstract: Synthetic ligand compounds and methods of differentiating between Shiga toxin 1 and Shiga toxin 2 are disclosed herein. Another embodiment includes a kit for differentiating between Shiga toxin 1 and Shiga toxin 2. Assay systems and methods for providing an assay are also provided for herein.Type: ApplicationFiled: April 16, 2008Publication date: February 12, 2009Inventors: Suri Saranathan Iyer, Duane Michael Hatch, Ramesh Ratan Kale, Alison Ann Weiss, Shantini Gamage, Colleen M, McGannon
-
Patent number: 7482439Abstract: Caprazene and caprazol could be synthesized by hydrolysis of a caprazamycin. There could be synthesized a caprazene-1??-amide derivative of the formula (II) and a caprazene-1??-ester derivative of the formula (III) from caprazene. Further, there could be synthesized a caprazol-1??-amide derivative of the formula (V) and a caprazol-1??-amide-3??-ester derivative and a caprazol-3??-ester derivative, etc. from caprazol. Furthermore, an imidazolidinone derivative could be synthesized from the ring-opened product of the 1,4-diazepinone ring of caprazol. The novel caprazene derivative, novel caprazol derivative and novel imidazolidinone derivative now synthesized exhibit excellent antibacterial activities against a variety of bacteria, including acid-fast bacteria.Type: GrantFiled: January 30, 2004Date of Patent: January 27, 2009Assignees: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Meiji Seika Kaisha, Ltd.Inventors: Toshiaki Miyake, Masayuki Igarashi, Tetsuo Shitara, Yoshiaki Takahashi, Masa Hamada
-
Publication number: 20080261901Abstract: The present invention is related to novel cosmetic composition comprising ?-fructosyl-L-ascorbic acid derivatives produced by fructose conversion reaction using by ascorbic acid and the compounds shows potent inhibiting effect on the activity of tyrosinase enzyme, therefore, it can be useful as a skin whitening cosmetic composition as an cream, skin, lotion, pack and the like.Type: ApplicationFiled: February 23, 2005Publication date: October 23, 2008Applicant: BIOLAND LTD.Inventors: Ki Ho Kim, Sang Ki Rhee, Chul Ho Kim, Kang Il Ko, Soo Nam Park, Sang Min Lee
-
Patent number: 7323452Abstract: A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as catalysts or “pseudo” enzymes for the oxidation. These additives include multivalent transition metal ions, as well as complexes thereof, and NAD+ which enhance the oxidation reaction. The method described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.Type: GrantFiled: December 20, 2004Date of Patent: January 29, 2008Assignee: Wardan, L.L.C.Inventors: Ward B. Bowen, Jr., Daniel S. Daniel
-
Patent number: 7157078Abstract: This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containing a) a termiticide selected such that the termiticide causes death to about 50 to about 100% of termites within about 24 to about 84 days after the termites begin to ingest the termiticide or the bait matrix comprising the termiticide, b) a cellulose containing material, and c) water. The termiticidal bait matrix can be used in a bait station installed in the ground. The kits are suitable to be used by consumers in their homes.Type: GrantFiled: February 2, 2004Date of Patent: January 2, 2007Assignee: The University of Florida Research Foundation, Inc.Inventors: Philip Frederick Brode, III, Garry Steven Garren, Leo Timothy Laughlin, Randall Stryker Matthews, Dale Edwin Barker, Daniel James Kinne, Gary Eugene McKibben, Christopher Miles Miller, Timothy Robert Probst
-
Patent number: 7153877Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.Type: GrantFiled: December 9, 2004Date of Patent: December 26, 2006Assignee: Interhealth Nutraceuticals IncorporatedInventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
-
Patent number: 7119110Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.Type: GrantFiled: October 4, 2002Date of Patent: October 10, 2006Assignee: Interhealth Nutraceuticals IncorporatedInventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
-
Patent number: 7094431Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.Type: GrantFiled: September 30, 2003Date of Patent: August 22, 2006Inventor: Mickey L. Peshoff
-
Patent number: 7067494Abstract: This invention provides analogs of eleutherobin and the eleuthesides modified at the C-11 position or comprising an epoxide functionality from C-11 to C-12. C-11 to C-12 is an ideal location for conjugating functional moieties to the eleutherobin pharmacophore without significant loss of antimitotic activity. Moieties that may be conjugated at C-11 include those intended to increase the solubility of the pharmacophore, to facilitate drug formulation, or to facilitate in vivo delivery or targeting.Type: GrantFiled: June 25, 2002Date of Patent: June 27, 2006Assignee: The University of British ColumbiaInventors: Raymond J. Andersen, Michel Roberge, Robert A. Britton, E. Dilip De Silva
-
Patent number: 6939859Abstract: An dermatological agent for external use is disclosed which contains a chromanol glycoside represented by the following general formula (1) (wherein R1, R2, R3, and R4 which may be the same or different, each represent a hydrogen atom or a lower alkyl group, R5 represents a hydrogen atom, a lower alkyl group, or a lower acyl group, X represents a monosaccharic residue or an oligosaccharic residue optionally having the hydrogen atom of the hydroxyl group in the saccharic residue substituted with a lower alkyl group or a lower acyl group, n represents an integer in the range of 0-6, and m represents an integer in the range of 1-6). This is a novel dermatological agent for external use which excels in stability and percutaneous absorbency, manifests an effective action safely at a small application rate, and effectively prevents and cures the dermopathy.Type: GrantFiled: March 30, 2000Date of Patent: September 6, 2005Assignee: CCI Corp.Inventors: Hironobu Murase, Toshiaki Fujii
-
Patent number: 6916849Abstract: The present invention relates to compositions for lowering the total amount of cholesterol in the blood and methods of using the compositions. The compositions are a mixture of pravastatin and one or more vitamins selected from riboflavins, d-?-tocopherols, ascorbic acids and inositol hexanicotinate.Type: GrantFiled: May 1, 2003Date of Patent: July 12, 2005Assignee: Sankyo Company, LimitedInventors: Tsuneki Ohsawa, Ikuo Takagi, Ippei Shimizu, Tatsuhito Kondo, Masato Nakayama, Yasuhiro Torizumi
-
Patent number: 6913772Abstract: The present invention relates to a composition useful for hepatoprotection, said composition comprising polar extract of plant Cryptolepis Buchanani and/or fractions of the said extract, and optionally pharmaceutically acceptable additives and a method of producing said composition and also a method of treating a subject using said composition.Type: GrantFiled: December 11, 2003Date of Patent: July 5, 2005Assignee: Council of Scientific and Industrial ResearchInventors: Ghulam Nabi Qazi, Bupinder Singh Jaggi, Bal Krishan Chandan, Krishan Avtar Suri, Naresh Kumar Satti, Rakesh Maurya, Lila Ram Manhas, Ashwani Kumar, Bal Krishan Kapahi